Mrs. Erin E Rowlson, M.S. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1875 Northwestern Ave S, Stillwater, MN 55082 Phone: 651-439-4840 |
Mrs. Amy Jo Finn, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1875 Northwestern Ave S, Stillwater, MN 55082 Phone: 651-439-4840 Fax: 651-439-4894 |
Hannah Driver, MS, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 14949 62nd St N, Stillwater, MN 55082 Phone: 612-364-2949 |
Brooke D Nielsen, LMFT Marriage & Family Therapist Medicare: Medicare Enrolled Practice Location: 1751 Tower Dr W Ste 200, Stillwater, MN 55082 Phone: 651-439-2059 Fax: 888-675-8262 |
Janet Sterk, M.A., L.M.F.T. Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 305 Greeley St S, #302, Stillwater, MN 55082 Phone: 651-351-0032 |
Kari Kelcher, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1875 Northwestern Ave S, Stillwater, MN 55082 Phone: 651-439-4840 Fax: 651-439-4894 |
News Archive
Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. ("Zogenix") based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.
Proscia, a cloud-delivered solutions provider for digital pathology, today announced the release of a series of new features including Proscia Connect.
The Society of Gynecologic Oncologists has published its third in a series of four papers on a variety of cervical cancer issues and topics featured at "The Future Strategies for Cervical Cancer Prevention: What Do We Need to Do Now to Prepare" Forum. The paper, entitled "Can the Barriers to HPV Vaccination in High-Risk Populations be Overcome?" appears in the June, 2010 issue of Gynecologic Oncology Journal.
Techne Corporation, d/b/a Bio-Techne, announced today that it has made a $10 million equity investment in CyVek, Inc. (CyVek), with a commitment to acquire CyVek if certain future milestones are met.
› Verified 9 days ago